Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics' stock has been impacted by several key events in the past six months. The company reported mixed Q3 and Q4 2025 earnings, with a significant stock decline after the Q4 report due to the announced departure of its largest customer. Fulgent Genetics completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. Q1 2026 financial results reported a GAAP and non-GAAP loss, but the EPS exceeded analysts' expectations. The company reaffirmed its full-year 2026 revenue guidance, but analyst price targets have been lowered, and the stock has experienced a decrease of 39.2% since the start of 2026.

Fulgent Genetics experiences significant volatility in the demand for its genetic testing services. The demand for its COVID-19 tests has varied widely, depending on factors such as the emergence or reemergence of viral variants. These demand fluctuations can substantially impact the company's performance between periods.

Fulgent Genetics, Inc. is a technology-based company in the Healthcare sector, specializing in genetic testing and therapeutic development. It provides genetic testing services to physicians, offering clinically actionable diagnostic information through its technology platforms. Fulgent's products and services include single-gene tests and multi-gene panels for various genetic conditions, and it owns Picture Genetics, a consumer-oriented testing subsidiary. The company is also involved in therapeutic development, focusing on drug candidates for various cancers.

Fulgent Genetics, Inc. is headquartered in El Monte, California, U.S. The company's primary geographic market is the United States, which accounts for the vast majority of its revenue, but it also has a foreign geographic segment. The company has been actively expanding its geographic footprint through initiatives like adding new lab locations and building a nationwide commercial infrastructure, partly through acquisitions.

In the past year, Fulgent Genetics' brand reputation has faced some challenges. Investor alerts and investigations by law firms suggest scrutiny and potential legal concerns. There is a perception among some investors that the market may be undervaluing Fulgent Genetics, viewing it primarily as a laboratory rather than recognizing its potential as a software and data-driven company with AI capabilities.

Fulgent Genetics, Inc. has a mixed ownership structure, with significant institutional and insider holdings. Institutional ownership accounts for 53.66% of the company, with major institutional shareholders including BlackRock, Inc. and Vanguard Group Inc. The largest individual shareholder is Ming Hsieh, the founder, Chairman, and CEO, who owns 28.61% of the company. Insider ownership stands at 8.47%, and the general public holds a 10% stake.